BioReperia
PrivateLast Round
Grant
Apr 13, 2021
Total Funding Raised
$1.7M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
BioReperia operates in Healthcare & Life Sciences and is based in Linköping. Its latest recorded funding round was a Grant round in April 2021.
BioReperia is a biotechnology company that provides a zebrafish tumor xenograft (ZTX®) platform used to accelerate drug discovery and predict the efficacy of cancer treatments for personalized medicine.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioReperia Comparables
Compare BioReperia with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ZeClinics | 84% | |
| Hunter Biotechnology | 78% | |
| Zefit | 77% |
For institutional investors. Book with your work email.
BioReperia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 13, 2021 | ||||
| Series A | Jul 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioReperia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LiU Invest | Seed |
| Almi Invest AB | Series A |
| Swelife | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 85% MoM.
- Aug 20, 2026
Monthly visitors increased 43% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withAug 12, 2026
BioReperia partners with Telomir Pharmaceuticals, Inc. on ZTX(R)-platform research evaluating Telomir-Zn in triple-negative breast cancer models, with the resulting data published and contributing to Telomir Pharmaceuticals, Inc.'s IND clearance in Apr '26.
For institutional investors. Book with your work email.
BioReperia Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioReperia's valuation, stock price, and market status.
Is BioReperia a public or private company?
BioReperia is a private company.
What is the current stock price of BioReperia?
BioReperia is a private company, so its shares have no public market price. Caplight tracks BioReperia's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioReperia worth (valuation)?
Valuation information for BioReperia is not publicly available.
Can I buy BioReperia stock?
BioReperia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioReperia's last funding round?
BioReperia's most recent funding round was Grant on April 13, 2021.
Who are the main investors in BioReperia?
Key investors in BioReperia include Almi Invest AB.
Will BioReperia IPO soon?
No public IPO plans have been announced for BioReperia.
How can I track BioReperia secondary market activity?
Caplight tracks bids, offers, and trades in BioReperia's shares on secondary markets.